CytoDyn is in late-stage clinical development of leronlimab, a CCR5 receptor antagonist, to be used as a platform drug for various therapeutic indications, including NASH, NASH/HIV, oncology, and HIV. The CCR5 receptor is a protein located on the surface of various cells including white blood cells, stellate cells which produce scar tissue in the liver, cells that undergo malignant transformation, and is the predominant co-receptor needed for certain strains of HIV to infect healthy T-cells. The CCR5 receptor serves as a receptor for chemical attractants called chemokines. Chemokines are the key orchestrators of leukocyte trafficking by attracting immune cells to the sites of inflammation. Leronlimab is a humanized monoclonal antibody that is a once-a-week subcutaneous injection that can also be administered intravenously. Leronlimab is a competitive rather than allosteric inhibitor of the CCR5 receptor. This mechanism of action of binding competitively to the CCR5 receptor differentiates leronlimab from all other CCR5 antagonists.
我们正在追踪 CytoDyn 的市场扩张
CytoDyn 的国际扩张与竞争对手的对比情况
CytoDyn你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 CytoDyn你 | 0 | 0 | — | 0 | 0 |
当前没有招聘
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
没有进行中的营销活动
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
CytoDyn 为三阴性乳腺癌患者启动扩大使用计划，推进首创人源化单克隆抗体 leronlimab 的研发。
CytoDyn公布leronlimab治疗转移性三阴性乳腺癌患者的存活数据令人鼓舞，显示潜在治疗效益。
CytoDyn已完成其第二阶段转移性结直肠癌研究的招募,在美国七个临床地点招募了超过60名患者。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 CytoDyn 的业务、市场和增长信号的快速解答。
